Business
Tandem Diabetes Care Presents Positive Real-World Data from Pediatric Users of t:slim X2 Insulin Pump with Basal-IQ Technology at International Conference
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced
About this update from Tandem Diabetes Care, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nTandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced presentation of real-world data from pediatric users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend technology at the 45th annual conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD). Data from 2,696 users under the age of 18 years old showed an overall rate of hypoglycemia of only 0.9 percent when using Basal-IQ technology. A subgroup of users with at least 21 days of sensor-augmented pump data prior to use of Basal-IQ technology demonstrated a 31 percent reduction in hypoglycemia following introduction of the feature (n=491).\n\n\nData Highlights\n\n\nThe study included de-identified real-world data uploaded to Tandem’s t:connect® web application between August 31, 2018 and March 14, 2019, which was retrospectively analyzed to assess hypoglycemia outcomes.\n\n\nOverall Group (n=2,696) – The overall rate of hypoglycemia (defined as percent median time spent with sensor readings","length":1354,"tagName":"div"}]